Neoadjuvant platinum-based chemotherapy and lymphadenectomy for penile cancer: an international, multi-institutional, real-world study.

Autor:	Rose KM; Ochsner Medical Center, New Orleans, LA, USA., Pham R; University of Texas Health Science Center Houston, Houston, TX, USA., Zacharias NM; University of Texas M.D. Anderson Cancer Center, Houston, TX, USA., Ionescu F; H. Lee Moffitt Cancer Center, Tampa, FL, USA., Paravathaneni M; H. Lee Moffitt Cancer Center, Tampa, FL, USA., Marchetti KA; H. Lee Moffitt Cancer Center, Tampa, FL, USA., Sanchez D; University of Texas Health Science Center Houston, Houston, TX, USA.; University of Texas M.D. Anderson Cancer Center, Houston, TX, USA., Mustasam A; H. Lee Moffitt Cancer Center, Tampa, FL, USA., Sandstrom R; H. Lee Moffitt Cancer Center, Tampa, FL, USA., Vikram R; University of Texas M.D. Anderson Cancer Center, Houston, TX, USA., Dhillon J; H. Lee Moffitt Cancer Center, Tampa, FL, USA., Rao P; University of Texas M.D. Anderson Cancer Center, Houston, TX, USA., Schneider A; H. Lee Moffitt Cancer Center, Tampa, FL, USA., Pagliaro L; Mayo Clinic, Rochester, MN, USA., Alifrangis C; University College London Hospitals, London, UK., Albersen M; University Hospitals Leuven, Leuven, Belgium., Roussel E; University Hospitals Leuven, Leuven, Belgium., Master VA; Winship Cancer Institute of Emory University, Atlanta, GA, USA., Nazha B; Winship Cancer Institute of Emory University, Atlanta, GA, USA., Hernandez C; Vanderbilt University Medical Center, Nashville, TN, USA., Moses KA; Vanderbilt University Medical Center, Nashville, TN, USA., Protzel C; University Hospital of Rostock, Rostock, Germany., Montgomery J; University of Michigan, Ann Arbor, MI, USA., Angel M; Instituto Alexander Fleming, Buenos Aires, Argentina.; Instituto Misionero del Cancer, Posadas, Misiones, Argentina., Tobias-Machado M; Cancer Institute Dr Arnaldo, Sao Paulo, Brazil., Spiess PE; H. Lee Moffitt Cancer Center, Tampa, FL, USA., Pettaway CA; University of Texas M.D. Anderson Cancer Center, Houston, TX, USA., Chahoud J; H. Lee Moffitt Cancer Center, Tampa, FL, USA.
Jazyk:	angličtina
Zdroj:	Journal of the National Cancer Institute [J Natl Cancer Inst] 2024 Jun 07; Vol. 116 (6), pp. 966-973.
DOI:	10.1093/jnci/djae034
Abstrakt:	Introduction: This study investigated the efficacy and safety of neoadjuvant chemotherapy for locally advance penile squamous cell carcinoma for which current evidence is lacking. Methods: Included patients had locally advanced penile squamous cell carcinoma with clinical lymph node metastasis treated with at least 1 dose of neoadjuvant chemotherapy prior to planned consolidative lymphadenectomy. Objective response rates were assessed using Response Evaluation Criteria in Solid Tumors v1.1. The primary and secondary outcomes were overall survival and progression-free survival, estimated by the Kaplan-Meier method. Treatment-related adverse events were graded per the Common Terminology Criteria for Adverse Events v5.0. Results: A total of 209 patients received neoadjuvant chemotherapy for locally advanced and clinically node-positive penile squamous cell carcinoma. The study population consisted of 7% of patients with stage II disease, 48% with stage III, and 45% with stage IV. Grade 2 treatment-related adverse events occurred in 35 (17%) patients, and no treatment-related mortality was observed. Of the patients, 201 (97%) completed planned consolidative lymphadenectomy. During follow-up, 106 (52.7%) patients expired, with a median overall survival of 37.0 months (95% confidence interval [CI] = 23.8 to 50.1 months) and median progression-free survival of 26.0 months (95% CI = 11.7 to 40.2 months). Objective response rate was 57.2%, with 87 (43.2%) having partial response and 28 (13.9%) having a complete response. Patients with objective response to neoadjuvant chemotherapy had a longer median overall survival (73.0 vs 17.0 months, P < .01) compared with those who did not. The lymph node pathologic complete response rate was 24.8% in the cohort. Conclusion: Neoadjuvant chemotherapy with lymphadenectomy for locally advanced penile squamous cell carcinoma is well tolerated and active to reduce the disease burden and improve long-term survival outcomes. (© The Author(s) 2024. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu